Cyclomaltoheptaose mixed esters of anti-inflammatory drugs and short-chain fatty acids and study of their enzymatic hydrolysis in vitro

Carbohydrate Research

Volumn 344, Issue 4, 2009, Pages 526-530

  Cao, Feng ^a,b   Ren, Yong ^b   Hua, Weiyi ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING NORMAL UNIVERSITY   (China)

Author keywords

Cyclodextrin esters; Anti inflammatory drug esters; Biphenyl acetic acid; Colon specific drug delivery; Enzymatic hydrolysis

Indexed keywords

ANTI-INFLAMMATORY DRUG ESTERS; BIPHENYL ACETIC ACID; COLON-SPECIFIC DRUG DELIVERY; COLONIC CONTENTS; CYCLODEXTRIN CORES; ESTER BONDS; FLURBIPROFEN; IN-VITRO; LOADING CAPACITIES; MIXED ESTERS; OH GROUPS; PROPIONIC; SHORT-CHAIN FATTY ACIDS;

ACETIC ACID; ACIDS; DRUG DELIVERY; DRUG PRODUCTS; ENZYMATIC HYDROLYSIS; ESTERIFICATION; METAL ANALYSIS; PH EFFECTS;

ESTERS;

ACETIC ACID; AMYLASE; ANTIINFLAMMATORY AGENT; BETA CYCLODEXTRIN; ESTER DERIVATIVE; ESTERASE; FELBINAC; FLURBIPROFEN; HEPTAKIS(2,3 DI O ACETYL 6 DEOXY 6 IODO)CYCLOMALTOHEPTAOSE; HEPTAKIS(2,3 DI O PROPANOYL 6 DEOXY 6 IODO)CYCLOMALTOHEPTAOSE; HEPTAKIS[(2,3 O BUTANOYL 6 O 2 (4 ISOBUTYLPHENYL)PROPIONOYL]CYCLOMALTOHEPTAOSE; HEPTAKIS[(2,3 O PROPANOYL 6 O 2 (4 ISOBUTYLPHENYL) PROPIONOYL]CYCLOMALTOHEPTAOSE; HEPTAKIS[2,3 DI O ACETYL 6 O 2 (2 FLUORO 4 BIPHENYLYL)PROPIONOYL]CYCLOMALTOHEPTAOSE; HEPTAKIS[2,3 DI O ACETYL 6 O 2 (4 ISOBUTYLPHENYL)PROPIONOYL)]CYCLOMALTOHEPTAOSE; HEPTAKIS[2,3 DI O ACETYL 6 O 2 (BIPHENYL 4 YL) ETHANOYL]CYCLOMALTOHEPTAOSE; HEPTAKIS[2,3 DI O BUTANOYL 6 O 2 (2 FLUORO 4 BIPHENYLYL) ETHANOYL]CYCLOMALTOHEPTAOSE; HEPTAKIS[2,3 DI O BUTANOYL 6 O 2 (BIPHENYL 4 YL) ETHANOYL] CYCLOMALTOHEPTAOSE; HEPTAKIS[2,3 DI O BUTANOYL 6 O 2 (BIPHENYL 4 YL) ETHANOYL]CYCLOMALTOHEPTAOSE; HEPTAKIS[2,3 DI O PROPANOYL 6 O 2 (2 FLUORO 4 BIPHENYLYL) PROPIONOYL]CYCLOMALTOHEPTAOSE; HEPTAKIS[2,3 DI O PROPANOYL 6 O 2 (BIPHENYL 4 YL) ETHANOYL]CYCLOMALTOHEPTAOSE; IBUPROFEN; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG;

ARTICLE; DRUG CONJUGATION; DRUG DESIGN; DRUG SYNTHESIS; HALF LIFE TIME; HYDROLYSIS; IN VITRO STUDY; PRIORITY JOURNAL;

ALPHA-AMYLASES; ANTI-INFLAMMATORY AGENTS; BETA-CYCLODEXTRINS; ESTERASES; ESTERS; FATTY ACIDS; HYDROLYSIS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR;

EID: 60849101049     PISSN: 00086215     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carres.2008.10.001     Document Type: Article

References (16)

1. Sinha V., Singh A., Kumar R.V., Singh S., Kumria R., and Bhinge J. Crit. Rev. Ther. Drug Carrier Syst. 24 (2007) 63-92
2. Patel M., Shah T., and Amin A. Crit. Rev. Ther. Drug Carrier Syst. 24 (2007) 147-202
3. Hirayama F., Minami K., and Uekama K. J. Pharm. Pharmacol. 48 (1996) 27-31
4. Uekama K., Minami K., and Hirayama F. J. Med. Chem. 40 (1997) 2755-2761
5. Yano H., Hirayama F., Arima H., and Uekama K. J. Pharm. Sci. 90 (2001) 493-503
6. Zou M., Okamoto H., Cheng G., Hao X., Sun J., Cui F., and Danjo K. Eur. J. Pharm. Biopharm. 59 (2005) 155-160
7. Hirayama F., Ogata T., Yano H., Arima H., Udo K., Takano M., and Uekama K. J. Pharm. Sci. 89 (2000) 1486-1495
8. Berberan-Santos M.N., Canceill J., Brochon J.C., Jullien L., Lehn J.M., Pouget J., Tauc P., and Valeur B. J. Am. Chem. Soc. 114 (1992) 6427-6436
9. Ashton P.R., Koniger R., Stoddart J.F., Alker D., and Harding V.D. J. Org. Chem. 61 (1996) 903-908
10. Jodal I., Kandra L., Harangi J., Nanasi P., and Szejtli J. Starch 36 (1984) 140-143
11. Murayama T., Tanabe T., Ikeda H., and Ueno A. Bioorg. Med. Chem. 14 (2006) 3691-3696
12. Suetsugu N., Koyama S., Takeo K., and Kuge T. J. Biochem. 76 (1974) 57-63
13. Challa R., Ahuja A., Javed A., and Khar R.K. AAPS. Pharm. Sci. Tech. 6 (2005) 329-357
14. Mundargi R.C., Patil S.A., Agnihotri S.A., and Aminabhavi T.M. Drug Dev. Ind. Pharm. 33 (2007) 255-264
15. Du X.L., Zhang H.S., Deng Y.H., and Wang H. J. Chromatogr., A. 1178 (2007) 92-100
16. Baer H.H., Berenguel A.V., Shu Y.Y., Defaye J., Gadelle A., and Gonzalez F.S. Carbohydr. Res. 228 (1992) 307-314